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Background: Although the added value of increasing extent of glioblastoma 
resection is still debated, multiple technologies can assist neurosurgeons in 
attempting to achieve this goal. Intraoperative magnetic resonance imaging (iMRI) 
might be helpful in this context, but to date only one randomized trial exists.
Methods: We included 14 adults with a supratentorial tumor suspect for 
glioblastoma and an indication for gross total resection in this randomized 
controlled trial of which the interim analysis is presented here. Participants were 
assigned to either ultra‑low‑field strength iMRI‑guided surgery (0.15 Tesla) or to 
conventional neuronavigation-guided surgery (cNN). Primary endpoint was residual 
tumor volume (RTV) percentage. Secondary endpoints were clinical performance, 
health-related quality of life (HRQOL) and survival.
Results: Median RTV in the cNN group is 6.5% with an interquartile range of 
2.5‑14.75%. Median RTV in the iMRI group is 13% with an interquartile range of 3.75‑
27.75%. A Mann‑Whitney test showed no statistically significant difference between 
these groups (P = 0.28). Median survival in the cNN group is 472 days, with an 
interquartile range of 244‑619 days. Median survival in the iMRI group is 396 days, with 
an interquartile range of 191‑599 days (P = 0.81). Clinical performance did not differ 
either. For HRQOL only descriptive statistics were applied due to a limited sample size.
Conclusion: This interim analysis of a randomized trial on iMRI‑guided glioblastoma 
resection compared with cNN-guided glioblastoma resection does not show an 
advantage with respect to extent of resection, clinical performance, and survival 
for the iMRI group. Ultra‑low‑field strength iMRI does not seem to be cost‑effective 
compared with cNN, although the lack of a valid endpoint for neurosurgical studies 
evaluating extent of glioblastoma resection is a limitation of our study and previous 
volumetry-based studies on this topic.
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INTRODUCTION
Glioblastoma is an infiltrating malignant brain tumor. 
Standard treatment consists of surgery, radiotherapy, 
and chemotherapy, leading to a median survival of 
14.6 months.[21] The role of surgery is still under debate, 
though mounting evidence suggests that increased 
extent of tumor resection (EOTR) is associated with 
prolonged overall survival.[13]
Intraoperative magnetic resonance imaging (iMRI) is a 
tool to maximize EOTR, but many reports on its efficacy 
suffer from methodological flaws.[5] A recently published 
randomized controlled trial (RCT) demonstrated that iMRI 
leads to increased EOTR in comparison to conventional 
surgery, comparable to the use of 5-aminolaevulinic 
acid.[17]
In this paper, we present the results of an interim analysis 
of an international multicenter RCT that compares 
iMRI with conventional neuronavigation (cNN) for the 
neurosurgical treatment of glioblastoma. The objective 
is to assess whether iMRI-guided surgery leads to 
increased EOTR compared with cNN-guided surgery, 
and whether health-related quality of life (HRQOL) 
differs between these two approaches. We consulted the 
CONSORT (Consolidated Standards of Reporting Trials) 
2010 guidelines for reporting of this trial.[16]
The study protocol is registered at ClinicalTrials.gov under 
number NCT00943007 and has been approved by the 




We included 14 patients between March 2010 and 
July 2012 from all participating centers for the interim 
analysis of this RCT. Inclusion criteria were: Supratentorial 
brain tumor-suspected to be glioblastoma on 
contrast-enhanced diagnostic MRI, indication for gross 
total resection (GTR) of the tumor, age 18 years or older, 
WHO Performance Scale (WPS) 2 or better, ASA class 3 
or better, adequate knowledge of the Dutch or French 
language, and informed consent. Exclusion criteria were: 
Recurrent brain tumor, multiple brain tumor localizations, 
earlier skull radiotherapy, earlier chemotherapy for 
glioblastoma, chronic kidney disease or other renal 
function disorder, and a known MR-contrast allergy.
Sample size
To reduce the chance for type I errors (false positive) we 
used an alpha value of 0.05. To reduce the chance for 
type II errors (false negative) we used a beta value of 0.2 
leading to a power of 0.8. We considered a 10% additional 
resection of the preoperative tumor volume as the 
minimal clinically relevant difference, with an estimated 
standard deviation of approximately 12%.[12,15] This led 
to 23 patients in each treatment group. To compensate 
for loss to follow-up we intended to include a total of 
54 patients for the complete study.
Interventions
Experimental group
Within 72 h before surgery, a standard neuronavigation 
MRI scan was made at 1.5 Tesla (T) or 3T according to 
the local neurooncology protocol (T1 1 mm isovoxel after 
administration of a gadolinium-based contrast agent). 
Patients were operated in the iMRI operating room 
setup, using the Stealth Station neuronavigation system, 
Medtronic Polestar N20 (0.15T) moveable magnet and 
the Starshield® tent as a mobile Faraday cage for shielding 
radiofrequency noise (Medtronic Navigation, Louisville, 
CO). The head was fixed in a MR compatible head holder, 
and specific MR compatible anesthesia equipment 
was used (monitor, ECG pads, thermometer). No other 
precautions needed to be taken because of iMRI, and 
regular instruments could be used. A first nonenhanced 
T1 iMRI scan was usually made before starting surgery, 
but this was not mandatory. When the neurosurgeon 
considered glioblastoma resection to be complete, at least 
one intraoperative T1 7 min 4 mm scan was made after 
administration of contrast agent. In all but one case a 
so-called “double-dose” of contrast was used (0.2 mmol/kg). 
The neurosurgeon judged whether the scan demonstrated 
residual tumor, and decided either to continue resection if 
feasible and perform a new scan afterwards, or to finish the 
procedure after the intraoperative scan. If residual tumor 
was suspected, the “resection-scan-cycle” was repeated 
until the neurosurgeon considered glioblastoma resection 
to be maximal. Within 48 h after surgery, a regular control 
MRI scan was made including a contrast-enhanced T1 
multi-planar reconstruction MR scan (1 mm isovoxel).
Control group
The preoperative and postoperative imaging was the same 
as in the treatment group, only the surgical procedure 
differed. Patients were operated in a regular operating 
room setup using the Stealth Station neuronavigation 
system (Medtronic Navigation, Louisville, CO). The head 
was fixed in a standard Mayfield headclamp, and regular 
instruments were used. The surgery was finished at 




Residual tumor volume (RTV) percentage is used as the 
primary endpoint to assess EOTR. Pre - and postoperative 
tumor volume was calculated by segmenting 
the hyperintense area on contrast-enhanced T1 
MRI (including enclosed central necrosis) and subtracting 
the hyperintense area on native T1 MRI to compensate 
for blood in the resection cavity. Measurements were 
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performed using OsiriX software (Pixmeo SARL, Bernex, 
Switzerland) on Mac OS X using a Wacom Bamboo pen 
mouse for contour drawing. Postoperative tumor volume 
was divided by preoperative tumor volume to calculate 
the fraction of RTV. Multiplying the fraction with 100% 
provided the RTV. In formula:
RTV = (postoperative contrast enhancement/preoperative 
contrast enhancement) ×100%
Secondary endpoints
We recorded baseline demographic characteristics (sex, 
age, length, weight) and corticosteroid use on study entry. 
Complications were monitored on the case record form. 
WPS was scored one day before surgery, one day after 
surgery and before discharge from the hospital. We also 
recorded HRQOL. The patient was asked to complete the 
EORTC QLQ-C30 questionnaire with the QLQ-BN20 brain 
cancer module, and the EuroQol EQ-5D questionnaires. 
The questionnaires were taken one day before surgery, 
before discharge and 3 months after surgery. Later we added 
“12 months after surgery” to allow for a more long-term 
follow up as well. Raw scores were calculated and converted 
to standardized scores using a linear transformation. Overall 
survival was recorded for all patients.
Randomization
Patients were randomized and allocated to either the cNN 
or iMRI group. Randomization was performed by the 
first author using TEN-ALEA software for randomization 
in clinical trials. This software is provided by the Trans 
European Network (http://www.tenalea.com/) and 
maintenance for The Netherlands is performed by the 
Netherlands Cancer Institute (http://www.nki.nl/). No 
randomization blocks were used. The neurosurgeon could 
not be blinded for the procedure. We did not intend 
to blind the physicians on the ward, nor the patients. 
Volumetric assessment of pre- and postoperative tumor 
volume was performed by a single blinded researcher.
Statistics
Descriptive statistics were used to express RTV, WPS 
and survival. Univariate analysis was used to express the 
difference between both treatment groups regarding 
RTV (Mann–Whitney test), WPS (Mann–Whitney test) and 
survival (Kaplan–Meier analysis using a log rank test). 
After checking whether the residuals of the regression 
analysis were normally distributed, multivariate analysis 
was used to express the independent contributions on 
the primary endpoint of age, sex, preoperative tumor 
volume, and histologically proven glioblastoma. For 
data entry and calculations, SPSS Statistics version 21 for 
Mac (IBM Corporation, Armonk, NY) was used.
RESULTS
Interim analysis
The decision to perform an interim analysis was 
approved by the institutional ethics research boards of 
the coordinating center. It was not part of the original 
research protocol, which we modified for several 
reasons. The main reason was that we estimated that 
our minimally required difference of 10% would not be 
consistent with the actual results. Meanwhile iMRI did 
prolong surgery time by 1.5-2 h. Also surgery was hindered 
by device-related limitations in the iMRI group, like 
suboptimal ergonomics and intermittent malfunction of 
the ultrasonic aspirator (CUSA Excel Ultrasonic Surgical 
Aspirator; Integra Radionics, Burlington, MA, USA) due 
to magnetic interference. Further, we noticed that patient 
inclusion took significantly longer than expected based 
on a previous study.[6] This was mainly related to the 
indication for GTR as an inclusion criterion: Patients in 
which preoperatively was decided to leave a small area of 
contrast enhancement untouched because of the vicinity 
of eloquent areas or to avoid significant opening of the 
ventricular system, were excluded.
Baseline data
After randomization, eight patients were assigned to 
the cNN group and six patients to the iMRI group. 
Participant flow is visualized in Figure 1. Mean age for the 
cNN group was 66 ± 8 years compared with 61 ± 5 years 
for the iMRI group. Eleven patients were operated in the 
Netherlands and three in Belgium. In both treatment 
groups, one surgery was performed in the left hemisphere, 
all other surgeries were in the right hemisphere. Tumors 
were located in all lobes, except for in the iMRI group 
where no parietal tumors were included. Histopathology 
revealed glioblastoma in all patients except for two, 
having a metastasis: One in the cNN group and one 
in the iMRI group. All patients received radiotherapy 
postoperatively, and most received chemotherapy with 
temozolomide. Further details are provided in Table 1.
Outcomes
Outcomes were analyzed for all patients according to an 
intention to treat principle. Imaging data were complete 
for all patients, but questionnaires contained some 
missing data (in particular HRQOL questionnaires).
Tumor volumetry results are displayed in Table 2. The 
first three columns represent volumetry results for 
preoperative contrast-enhanced MRI, postoperative native 
MRI and postoperative contrast-enhanced MRI. The 
“postgado only” column represents postoperative contrast 
enhancement (supposed to be residual tumor) and the 
last column displays rounded RTV values. Median RTV 
in the cNN group is 6.5% with an interquartile range of 
2.5-14.75%. Median RTV in the iMRI group is 13% with 
an interquartile range of 3.75-27.75%. A Mann-Whitney 
test showed no statistically significant difference between 
these groups (P = 0.28). When both patients with a 
metastasis are excluded for further analysis, median 
RTV in the cNN group is 5% with an interquartile range 
of 2–16% and median RTV in the iMRI group is 9% 
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with an interquartile range of 3.5-33.5%. Also, for the 
glioblastoma population, a Mann-Whitney test did not 
show a statistically significant difference between these 
groups (P = 0.43). Multivariate analysis does not reveal 
any significant influence of sex, age, preoperative tumor 
volume, or histological diagnosis on RTV.
Median preoperative WPS is 1 for both treatment groups, 
ranging from 0 to 2. Median WPS one day postoperatively 
is 3 in the cNN group and 2.5 in the iMRI group, 
ranging from 1 to 3 in both groups. Median WPS before 
discharge (approximately one week after surgery in both 
groups) is 1 in both groups, ranging from 0 to 2. For the 
latter, data for one patient in the cNN group are missing. 
Using a Mann-Whitney test, mean rank for the WPS before 
discharge is 6.3 in the cNN group and 7.8 in the iMRI group. 
The difference is not statistically significant (P = 0.53).
Median survival in the cNN group is 472 days, with an 
interquartile range of 244-619 days. Median survival in 
the iMRI group is 396 days, with an interquartile range 
of 191-599 days. The corresponding log rank P 0.81. 
When both patients with a metastasis are excluded for 
further analysis, median survival is 539 days in the cNN 
group and 396 days in the iMRI group, with a log rank 
P 0.68. One glioblastoma patient in the cNN group 
opted for euthanasia 8 months after surgery due to late 
disease-related complications. If this patient is excluded 
from the latter analysis, median survival remains 
unchanged, with a log rank P 0.55.
Figure 2a shows a Kaplan-Meier curve that displays 
cumulative survival in time for both treatment groups, 
and Figure 2b shows the same curve excluding patients 
with a metastasis.
HRQOL scores are left out of this paper. Explorative data 
analysis does not show a clear advantage in HRQOL for either 
treatment group. After consultation of a health-technology 
assessment expert we decided to refrain from any further 
statistical analyses due to the small sample size.
Adverse events
One patient from the iMRI group suffered from 
postoperative hemorrhage, which led to prolonged 
hospital stay and cognitive impairment. No other adverse 
events or serious adverse events were reported.
DISCUSSION
Our study is the second RCT on glioblastoma surgery 
Figure 1:  Participant flow in the study
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using iMRI. This paper reports our results from an 
interim analysis of 14 patients. Volumetric assessment of 
the primary endpoint (RTV) does not show any advantage 
of iMRI-guided resection over cNN-guided resection: 
There is no statistical difference between both groups 
and mean RTV is higher in the iMRI group than in the 
cNN group. Clinical performance does not differ between 
both groups, and neither does survival in our population. 
Regarding HRQOL no firm conclusions could be 
drawn, although there is no clear tendency favoring one 
treatment group. Study inclusion has been halted based 
on the results of this interim analysis. The combination 
of the minimal difference between iMRI-based treatment 
and cNN-based treatment on the one hand and the slow 
inclusion rate on the other hand would lead to a much 
longer timeframe to achieve the statistically significant 
results we initially aimed for. Based on the present 
interim analysis, however, we do not expect a different 
conclusion, and by the time that statistical significance 
would be reached, the technology used in this study is 
likely to be replaced by new devices. Therefore, the 
necessary additional investments associated with the 
investigated iMRI technology (mainly increased time 
consumption in the operating theatre) does not seem 
justified in our opinion, and could even be considered as 
ethically inadequate.
Despite the small sample size, there is still a clear 
conclusion from this interim analysis, which differs from 
the conclusion of the only other iMRI RCT by Senft 
et al.[17] These authors concluded that iMRI-guided 
glioblastoma resection leads to GTR in 96% of cases 
compared with 68% in the control group (P = 0.023). 
Their control group consisted of a mixed population 
of cNN-guided resection and resection without 
neuronavigation. A post hoc exploratory analysis did 
not demonstrate a significant difference between both 
arms in the control group. Their definition of GTR 
was a tumor volume of less than 0.175 cm3 detected 
by a contrast-enhanced T1-weighted MRI, the same as 
used by Stummer et al.[21,20] The median postoperative 
volume of contrast-enhancing tissue was 0 cm3 in the 
iMRI group and 0.03 cm3 in the control group. No 
further details on their volumetry methodology are 
provided in the article. To our opinion, the authors’ 
conclusion favoring iMRI-guided glioblastoma 
Table 1: Study demographics










































BMI: Body mass index, SD: Standard deviation
Table 2: Tumor volumetry data (in cm3)
Patient Group Pregado Postnative Postgado Postgado only RTV
RACL01 cNN 35.4 19.6 25.2 5.8 16
RACL02 iMRI 14.6 13.6 20.2 6.5 45
RACL03 cNN 11.0 12.7 13.3 0.5 5
RACM01 cNN 23.2 1.0 1.6 0.6 2
RACM02 iMRI 120.0 6.3 10.8 4.5 4
RACM03 cNN 28.6 1.2 3.5 2.3 8
RACM04 cNN 30.9 0.4 1.7 1.3 4
RACM05 cNN 12.6 6.6 8.0 1.4 11
RACM06 iMRI 99.3 16.3 38.4 22.0 22
RACM07 iMRI 23.8 24.8 28.7 4.0 17
RACM08 iMRI 43.9 14.9 16.3 1.5 3
RACM09 iMRI 77.4 53.0 60.2 7.2 9
RACM10 cNN 154.0 48.5 52.1 3.6 2
RACM11 cNN 39.9 22.4 29.8 7.5 19
RTV: Residual tumor volume percentage
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resection should be seen in the context of a minimal 
difference in postoperative tumor volume between 
both treatment groups. No significant difference exists 
in progression-free survival, and most importantly: 
There is a lack of a valid methodology for volumetric 
assessment of glioblastoma resection.[6,13,23] In our 
opinion, tumor volumes reported in the study of Senft 
are within the error limits of tumor volumetry. Further, 
a clear definition of “tumor” is one of the challenges 
to be solved besides improving accuracy of glioblastoma 
volumetry itself. Both these factors are key in defining a 
valid endpoint to measure glioblastoma resection.
The widely cited study from Lacroix et al. states 
that a minimum of 98% glioblastoma resection is 
needed for survival benefit.[5,11] In that study, the 
authors used a method by which they assessed 
intraobserver agreement, but not interobserver 
agreement.[18] The same comments applies to the 
study by Kuhnt et al.[9,16] Sanai et al. reported a 
minimum of 78% glioblastoma resection needed for 
survival benefit.[12,14,15] These authors also used a 
volumetric approach based on manual segmentation 
of contrast-enhancing tissue on T1-weighted imaging, 
but did not describe any correction for hyperintense 
signal on native T1-weighted imaging, and did not 
report on intraobserver and interobserver agreement 
of their methodology. There is an ongoing discussion 
regarding an optimal approach to define and measure 
glioblastoma resection, and no consensus has been 
reached yet.[6,9,7,14,19,23] Therefore, in contrast to studies 
on radiotherapy and chemotherapy,[22,24] neurosurgical 
studies cannot yet benefit from a valid endpoint to 
measure glioblastoma resection, which limits external 
validity of individual study results. To minimize the 
error in respect to our own published data, we decided 
to have tumor volumes measured by a single (blinded) 
observer. We previously described this approach to have 
high intraobserver agreement, but low interobserver 
agreement.[6] Nevertheless, this type of approach is still 
the most commonly used approach to tumor volumetry 
in neurosurgical studies.[9,10,12]
A more fundamental discussion is to what extent 
further investments should be made to increase EOTR 
for glioblastoma surgery. Glioblastoma is a nonfocal 
disease in which tumor cells can be found far beyond 
the contrast-enhancing area.[1,2,3,8] As long as there is 
no valid endpoint to quantify glioblastoma resection, 
no firm conclusions can be drawn regarding the added 
value of GTR (or complete resection of enhancing 
tumor [CRET] as described by Vogelbaum et al.).[23] The 
minimal increase in patient survival after four decades 
of glioblastoma surgery (despite all sorts of technical 
equipment), in combination with no consensus on how 
to measure our results, may indicate that expanding 
technical innovation for glioblastoma resection should 
not have our highest priority at this moment.[4]
Limitations
The main limitation of this study is the lack of a valid 
endpoint for glioblastoma volumetry, as discussed before. 
We used the best available tumor volume definition but, 
still, our volumetry results should not be considered as 
absolute values, but more as a tendency in which the 
exact quantification can differ from the data provided in 
this article. Nevertheless, based on our previous study 
that analyzed intraobserver and interobserver agreement 
of glioblastoma volumetry, we are confident that the 
tendency reported in this article is a correct reflection of 
the results.[6]
Our interim analysis has a small sample size, which limits 
statistical significance in our endpoints. In particular, 
differences between HRQOL in both treatments groups 
Figure 2: Kaplan–Meier curve for (a) all patients, and (b) patients with a histologically proven glioblastoma
ba
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cannot be tested due to the small sample size aggravated 
by missing data.
Finally it should be noted that our data result from an 
0.15T iMRI system with its specific advantages and 
disadvantages. We do not expect different results on 
high-field strength systems, however, only because of a 
higher spatial resolution, but the use of other imaging 
modalities might lead to different conclusions. We also 
cannot make a valid comparison with 5-aminolevulinic 
acid (5-ALA) guided surgery,[20] which might be an 
interesting control group for a future comparative study 
with iMRI.
CONCLUSIONS
This interim analysis of a RCT on iMRI-guided 
glioblastoma resection compared with cNN-guided 
glioblastoma resection does not show an advantage 
with respect to EOTR, clinical performance, and 
overall survival for the iMRI group. Although the lack 
of a valid endpoint to measure glioblastoma resection 
prevents firm conclusions to be drawn, the added value 
of (ultra-low-field strength) iMRI for this nonfocal 
disease is to be debated seriously and does not seem to 
be cost-effective. Before evaluating new technological 
developments, research of the near future should 
primarily focus on developing a valid endpoint to 
compare surgical results, between different centers and 
with different technologies, as well as the assessment of 
survival benefits with increased EOTR.
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